BioreclamationIVT, a provider of biospecimens and related services, has acquired Asterand Bioscience, a global provider of high quality, well-characterized human tissue and research solutions with a focus on the oncology market. Asterand Bioscience advances drug research by accelerating target identification and biomarker validation, and improving drug candidate selection to increase the likelihood of clinical success.
“We are delighted that Asterand Bioscience’s talented staff is joining BioreclamationIVT. This is a great fit between two complementary companies,” said BioreclamationIVT Chief Executive Officer Jeff Gatz. “This acquisition will expand BioreclamationIVT’s portfolio of highly-annotated disease-state biospecimens. After combining Asterand Bioscience’s first-rate oncology tissue sourcing network with our existing strength in procuring disease-state tissue and clinical biofluids, BioreclamationIVT will become the market leader in disease-state biospecimens and a top resource for researchers focused on precision medicine. The addition of Asterand Bioscience’s tissue services and PhaseZERO research services groups will allow the combined company to offer a full research workflow solution, ranging from specimen sourcing through experimental design to data collection. BioreclamationIVT’s new offerings will include target and biomarker validation using histology and molecular techniques, and compound evaluation using cell-based model systems.”
“We are committed to extending BioreclamationIVT’s industry leading position through targeted investments and focused M&A activity,” said David Spaight, Chairman of BioreclamationIVT. “The acquisition of Asterand Bioscience is an important component of our strategy to provide biopharmaceutical researchers with the highest quality, well-annotated biospecimens and a full suite of scientific services.”
“We are pleased to be joining BioreclamationIVT and beginning the next phase of our company’s growth. It will be exciting to see the positive impact that our combined expertise and resources will have on diagnostic and drug development globally,” said Asterand Bioscience Chief Operating Officer and Chief Financial Officer John Canepa.
